Detection of Acetylsalicylic Acid and Omega-3 Fatty Acids in Schirmers' Test Strips Using Mass Spectrometry
NCT ID: NCT05775536
Last Updated: 2023-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
32 participants
INTERVENTIONAL
2021-01-21
2021-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
NCT02553772
The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
NCT01013077
Tear Osmolarity Clinical Utility in Dry Eye Disease
NCT02417116
The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease
NCT02260960
Tear Osmolarity Over Time With Artificial Tears
NCT01227226
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aspirin® 500 mg tablets
Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening Ingredients: 500 mg acetylsalicylic acid, Cellulose powder, maize starche
Aspirin 500Mg Tab
Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
Dr. Böhm® Omega 3 complex 870 mg
Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
Dr. Böhm® Omega 3 complex 870 mg
Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin 500Mg Tab
Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
Dr. Böhm® Omega 3 complex 870 mg
Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent prior to study-related procedures
* Normal ophthalmic findings
* No use of eye drops including topical lubricants in the 4 weeks before screening
Exclusion Criteria
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Presence or history of a severe medical condition as judged by the clinical investigator
* Intake of any drugs or dietary supplements within three weeks before the first study day (except contraceptives)
* TFBUT \<10 sec.
* Glaucoma in the medical history
* Ocular infection or clinically significant inflammation
* Ocular surgery in the 3 months preceding the study
* Pregnancy, planned pregnancy or lactating
* Known hypersensitivity to any component of the study medication
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doreen Schmidl
Assoc. Prof. Dr. Doreen Schmidl, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Vienna, Department of Clinical Pharmacology
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPHT-300920
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.